Want to join the conversation?
$BIIB said aducanumab, its investigational treatment for early Alzheimer's disease, was granted Fast Track designation by the U.S. FDA. Aducanumab is being evaluated in 2 Phase 3 studies, ENGAGE and EMERGE, to evaluate its safety and efficacy in slowing cognitive impairment and progression of disability in people with early Alzheimer's disease.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?